SynthesisHeart failure reviews2014
Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence.
Synthesis in Heart failure reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.Ontario health technology assessment series · 2021Pooled it
- Pooled it
- Japanese high bleeding risk criteria status predicts low thrombogenicity and bleeding events in patients undergoing percutaneous coronary intervention.Cardiovascular intervention and therapeutics · 2023Trial
- Correlation between mean platelet volume and B-type natriuretic peptide concentration in emergency patients with heart failure.Biochemia medica · 2015Trial
- Risk stratification of Stage B heart failure with BNP levels of 35-100 pg/mL: development of the PHASE Index from the CHART-2 Study.European heart journal open · 2026Article
- Diagnostic Performance of Guideline-Recommended B-Type Natriuretic Peptide Thresholds for Detecting Elevated Left Ventricular End-Diastolic Pressure.Diagnostics (Basel, Switzerland) · 2026Article
- Artificial Intelligence-enhanced Electrocardiography for Heart Failure Screening and Risk Stratification.Current heart failure reports · 2026Review
- Advancing Heart Failure Care Through Disease Management Programs: A Comprehensive Framework to Improve Outcomes.Journal of cardiovascular development and disease · 2025Review
- Heart failure risk stratification using artificial intelligence applied to electrocardiogram images: a multinational study.European heart journal · 2025Article
- Non-Inferiority Analysis of Electrocardiography Analysis Application vs. Point-of-Care Ultrasound for Screening Left Ventricular Dysfunction.Yonsei medical journal · 2025Article
- Identification of biomarkers and immune microenvironment associated with heart failure through bioinformatics and machine learning.Frontiers in molecular biosciences · 2025Article
- Improvement initiatives in the diagnostic process of heart failure: a scoping review.Frontiers in cardiovascular medicine · 2025Review
- Elevated B-type natriuretic peptide levels in pregnant women with hyperemesis gravidarum: a biomarker of cardiac stress?Revista da Associacao Medica Brasileira (1992) · 2025Article
- Accuracy of Lung Ultrasonography for Diagnosis of Heart Failure; a Systematic Review and Meta-analysis.Archives of academic emergency medicine · 2025Review
- Impedance Cardiography in the Diagnosis of Congestive Heart Failure: A Systematic Review and Meta-Analysis.Cureus · 2025Review
- Article
- Clinical usefulness of NT-proBNP as a prognostic factor for septic shock patients presenting to the emergency department.Scientific reports · 2024Article
- Insights into the Novel Cardiac Biomarker in Acute Heart Failure: Mybp-C.Life (Basel, Switzerland) · 2024Article
- Scalable Risk Stratification for Heart Failure Using Artificial Intelligence applied to 12-lead Electrocardiographic Images: A Multinational Study.medRxiv : the preprint server for health sciences · 2024Article
- Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.EClinicalMedicine · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our purpose was to determine the test performance characteristics of BNP and NT-proBNP in the diagnosis of heart failure for patients presenting to an emergency department or urgent care center. We searched Medline, Embase, AMED, Cochrane, Cochrane Database of Systematic Reviews, and CINAHL for English-language articles published between 1989 and June 2012. Studies were limited to those using FDA-approved assays. We examined test performance at three pre-specified cutpoints (manufacturers' suggested, researchers' optimal, and lowest) and considered the effect of age, gender, ethnicity and renal function. We used the QUADAS-2 tool to examine risk of bias and applicability, and the AHRQ Methods Guide to assess the strength of evidence. Seventy-six articles met our inclusion criteria, 37 examined BNP, 25 examined NT-proBNP, and 14 examined both. Pooled sensitivity and specificity for BNP at the three pre-specified cutpoints were 95, 91, and 95 % (sensitivity) and 55, 80, and 67 % (specificity), respectively. For NT-proBNP, sensitivity and specificity at the same cutpoints were 91, 90, and 96 % (sensitivity) and 67, 74, and 55 % (specificity). Both BNP and NT-proBNP perform well to rule out, but less well to rule in, the diagnosis of heart failure among persons presenting to emergency departments or urgent care centers. Both BNP and NT-proBNP levels are positively associated with age and negatively associated with renal function. However, the effect of these factors with respect to selecting optimal cutpoints is unclear. For BNP, 100 pg/mL appears to be a consensus cutpoint. No clear consensus has emerged for NT-proBNP, but the age-adjusted cutpoints of 450 pg/mL for <50 years, 900 pg/mL for 50-75 years and 1,800 pg/mL for >75 years appear promising and merit greater scrutiny and validation.
Indexed as
Identifiers
24957908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.